Northeast Pharmaceutical Group Co Ltd (000597) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Northeast Pharmaceutical Group Co Ltd (000597) has a cash flow conversion efficiency ratio of 0.049x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥274.09 Million ≈ $40.11 Million USD) by net assets (CN¥5.60 Billion ≈ $819.04 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Northeast Pharmaceutical Group Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Northeast Pharmaceutical Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Northeast Pharmaceutical Group Co Ltd carry for a breakdown of total debt and financial obligations.
Northeast Pharmaceutical Group Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Northeast Pharmaceutical Group Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ultra Jaya Milk Industry Tbk
JK:ULTJ
|
0.087x |
|
Shinyoung Securities Co. Ltd.
KO:001720
|
-0.156x |
|
DLG Exhibitions & Events Corp Ltd
SHG:600826
|
0.046x |
|
Guangzhou Newlife New Material Co. Ltd. A
SHE:301323
|
N/A |
|
Cansino Biologics Inc
SHG:688185
|
0.006x |
|
Liquidity Services Inc
NASDAQ:LQDT
|
-0.002x |
|
Coursera Inc
NYSE:COUR
|
0.009x |
|
Otokar Otomotiv ve Savunma Sanayi AS
IS:OTKAR
|
-0.203x |
Annual Cash Flow Conversion Efficiency for Northeast Pharmaceutical Group Co Ltd (1998–2024)
The table below shows the annual cash flow conversion efficiency of Northeast Pharmaceutical Group Co Ltd from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see Northeast Pharmaceutical Group Co Ltd (000597) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥5.57 Billion ≈ $815.01 Million |
CN¥758.76 Million ≈ $111.03 Million |
0.136x | +19.78% |
| 2023-12-31 | CN¥5.16 Billion ≈ $754.89 Million |
CN¥586.75 Million ≈ $85.86 Million |
0.114x | -51.64% |
| 2022-12-31 | CN¥4.71 Billion ≈ $689.70 Million |
CN¥1.11 Billion ≈ $162.22 Million |
0.235x | +35.17% |
| 2021-12-31 | CN¥4.29 Billion ≈ $627.80 Million |
CN¥746.51 Million ≈ $109.24 Million |
0.174x | +25.63% |
| 2020-12-31 | CN¥4.12 Billion ≈ $603.21 Million |
CN¥570.92 Million ≈ $83.54 Million |
0.138x | +53.89% |
| 2019-12-31 | CN¥3.92 Billion ≈ $573.30 Million |
CN¥352.60 Million ≈ $51.60 Million |
0.090x | +13.42% |
| 2018-12-31 | CN¥3.59 Billion ≈ $525.75 Million |
CN¥285.09 Million ≈ $41.72 Million |
0.079x | +167.13% |
| 2017-12-31 | CN¥2.55 Billion ≈ $372.85 Million |
CN¥-301.20 Million ≈ $-44.07 Million |
-0.118x | -174.83% |
| 2016-12-31 | CN¥2.43 Billion ≈ $356.17 Million |
CN¥384.51 Million ≈ $56.27 Million |
0.158x | +280.44% |
| 2015-12-31 | CN¥2.40 Billion ≈ $351.34 Million |
CN¥99.70 Million ≈ $14.59 Million |
0.042x | +144.00% |
| 2014-12-31 | CN¥2.76 Billion ≈ $404.05 Million |
CN¥46.99 Million ≈ $6.88 Million |
0.017x | +110.22% |
| 2013-12-31 | CN¥1.60 Billion ≈ $233.99 Million |
CN¥-266.38 Million ≈ $-38.98 Million |
-0.167x | -438.70% |
| 2012-12-31 | CN¥1.75 Billion ≈ $256.13 Million |
CN¥86.09 Million ≈ $12.60 Million |
0.049x | +136.74% |
| 2011-12-31 | CN¥1.74 Billion ≈ $255.03 Million |
CN¥-233.32 Million ≈ $-34.14 Million |
-0.134x | -208.03% |
| 2010-12-31 | CN¥2.07 Billion ≈ $302.24 Million |
CN¥255.96 Million ≈ $37.46 Million |
0.124x | -58.68% |
| 2009-12-31 | CN¥2.05 Billion ≈ $300.50 Million |
CN¥615.91 Million ≈ $90.13 Million |
0.300x | -33.40% |
| 2008-12-31 | CN¥1.57 Billion ≈ $230.40 Million |
CN¥709.03 Million ≈ $103.75 Million |
0.450x | +101.66% |
| 2007-12-31 | CN¥889.22 Million ≈ $130.12 Million |
CN¥198.56 Million ≈ $29.06 Million |
0.223x | +295.39% |
| 2006-12-31 | CN¥927.49 Million ≈ $135.72 Million |
CN¥-106.00 Million ≈ $-15.51 Million |
-0.114x | -192.34% |
| 2005-12-31 | CN¥900.07 Million ≈ $131.71 Million |
CN¥111.40 Million ≈ $16.30 Million |
0.124x | -48.16% |
| 2004-12-31 | CN¥884.02 Million ≈ $129.36 Million |
CN¥211.06 Million ≈ $30.88 Million |
0.239x | -9.70% |
| 2003-12-31 | CN¥870.26 Million ≈ $127.35 Million |
CN¥230.08 Million ≈ $33.67 Million |
0.264x | +46.67% |
| 2002-12-31 | CN¥873.28 Million ≈ $127.79 Million |
CN¥157.41 Million ≈ $23.03 Million |
0.180x | +101.95% |
| 2001-12-31 | CN¥883.36 Million ≈ $129.26 Million |
CN¥78.84 Million ≈ $11.54 Million |
0.089x | +123.72% |
| 2000-12-31 | CN¥905.53 Million ≈ $132.51 Million |
CN¥36.13 Million ≈ $5.29 Million |
0.040x | -36.48% |
| 1999-12-31 | CN¥869.73 Million ≈ $127.27 Million |
CN¥54.62 Million ≈ $7.99 Million |
0.063x | +926.23% |
| 1998-12-31 | CN¥999.14 Million ≈ $146.21 Million |
CN¥-7.59 Million ≈ $-1.11 Million |
-0.008x | -- |
About Northeast Pharmaceutical Group Co Ltd
Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals preparations, pharmaceutical business, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti-infection products, such as fosfomycin series, azithromycin series, amantadine series, berberine hydroch… Read more